Nausea is most pronounced during dose escalation windows, particularly around weeks six to eight when doses are increasing, and typically diminishes substantially by week twelve as tolerance develops
2 Management can be particularly challenging owing to the tumors potential for aggressive behavior, including local and distant metastasis in over one-third and approximately 44% of cases, respectively
Absolute risk remains low
A PbGST 3D structural homology model was generated by comparative modeling with the PfGST (PDB code 1Q4J) as a template (Figure 2B)
Thambiayya K, Wasserloos K, Kagan VE, Stoyanovsky D, Pitt BR
For those using BPC-157 to address gastrointestinal issues, this is often when digestive symptoms begin to stabilize more consistently